Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes?

Affiliations

¹ 1 Kaiser Permanente of Georgia and the Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA ; 2 Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA ; 3 Department of Biostatistics, University of Texas School of Public Health, Houston, TX, USA.

Joshua I Barzilay et al. Ann Transl Med. 2016 May.

. 2016 May;4(10):202.

doi: 10.21037/atm.2016.05.24.

¹ 1 Kaiser Permanente of Georgia and the Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA ; 2 Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA ; 3 Department of Biostatistics, University of Texas School of Public Health, Houston, TX, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo.
Messerli FH, Toklu B, Fakheri R, Bangalore S. Messerli FH, et al. Ann Transl Med. 2016 Aug;4(16):321. doi: 10.21037/atm.2016.08.11. Ann Transl Med. 2016. PMID: 27668241 Free PMC article. No abstract available.

The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo.
Messerli FH, Toklu B, Fakheri R, Bangalore S. Messerli FH, et al. Ann Transl Med. 2016 Aug;4(16):321. doi: 10.21037/atm.2016.08.11. Ann Transl Med. 2016. PMID: 27668241 Free PMC article. No abstract available.
Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
Malek V, Suryavanshi SV, Sharma N, Kulkarni YA, Mulay SR, Gaikwad AB. Malek V, et al. Rev Physiol Biochem Pharmacol. 2021;179:31-71. doi: 10.1007/112_2020_50. Rev Physiol Biochem Pharmacol. 2021. PMID: 32979084 Review.
Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications.
Kadakol A, Malek V, Goru SK, Pandey A, Gaikwad AB. Kadakol A, et al. Indian J Pharmacol. 2017 Sep-Oct;49(5):348-356. doi: 10.4103/ijp.IJP_710_16. Indian J Pharmacol. 2017. PMID: 29515275 Free PMC article.

1. Ruilope LM, Solini A. RAS blockade for every diabetic patient: pro and con. Diabetes Care 2011;34 Suppl 2:S320-4. 10.2337/dc11-s248 - DOI - PMC - PubMed
1. Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 2016;352:i438. 10.1136/bmj.i438 - DOI - PMC - PubMed
1. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997;46 Suppl 2:S104-11. 10.2337/diab.46.2.S104 - DOI - PubMed
1. Björck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43. 10.1136/bmj.304.6823.339 - DOI - PMC - PubMed
1. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62. 10.1056/NEJM199311113292004 - DOI - PubMed